Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher McCabe

Showing results (31-40 of 150) with videos related to

Pageof 15
Sort By:
Health Economics|September 24, 2004
Health state values for the HUI 2 descriptive system: results from a UK surveyChristopher McCabe, Katherine Stevens, Jennifer Roberts, et al.
International Journal of Technology Assessment in Health Care|June 21, 2007
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et alChristopher McCabe, Aki Tsuchiya, Karl Claxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?Richard Edlin, Peter Hall, Klemens Wallner, et al.
British Journal of Clinical Pharmacology|August 19, 2010
Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologistsRichard Edlin, Jeff Round, Claire Hulme, et al.
Current Vascular Pharmacology|October 27, 2005
Endothelin and the ischaemic heartCherry L Wainwright, Christopher McCabe, Kathleen A Kane
Pharmacoeconomics|May 11, 2017
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness ModelsChase Hollman, Mike Paulden, Petros Pechlivanoglou, et al.
Pharmacoeconomics|March 23, 2016
Cancer Drugs Fund 2.0: A Missed Opportunity?Christopher McCabe, Ash Paul, Greg Fell, et al.
Pharmacoeconomics|November 22, 2014
Value-based reimbursement decisions for orphan drugs: a scoping review and decision frameworkMike Paulden, Tania Stafinski, Devidas Menon, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 2, 2022
A Conceptual Framework for Life-Cycle Health Technology AssessmentErin Kirwin, Jeff Round, Ken Bond, et al.
Experimental & Translational Stroke Medicine|October 21, 2016
Therapeutic potential of the renin angiotensin system in ischaemic strokeMariana Moreira Coutinho Arroja, Emma Reid, Christopher McCabe
Pageof 15

Showing results (31-40 of 150) with videos related to

Sort By:
Pageof 15
Health Economics|September 24, 2004
Health state values for the HUI 2 descriptive system: results from a UK surveyChristopher McCabe, Katherine Stevens, Jennifer Roberts, et al.
International Journal of Technology Assessment in Health Care|June 21, 2007
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et alChristopher McCabe, Aki Tsuchiya, Karl Claxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?Richard Edlin, Peter Hall, Klemens Wallner, et al.
British Journal of Clinical Pharmacology|August 19, 2010
Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologistsRichard Edlin, Jeff Round, Claire Hulme, et al.
Current Vascular Pharmacology|October 27, 2005
Endothelin and the ischaemic heartCherry L Wainwright, Christopher McCabe, Kathleen A Kane
Pharmacoeconomics|May 11, 2017
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness ModelsChase Hollman, Mike Paulden, Petros Pechlivanoglou, et al.
Pharmacoeconomics|March 23, 2016
Cancer Drugs Fund 2.0: A Missed Opportunity?Christopher McCabe, Ash Paul, Greg Fell, et al.
Pharmacoeconomics|November 22, 2014
Value-based reimbursement decisions for orphan drugs: a scoping review and decision frameworkMike Paulden, Tania Stafinski, Devidas Menon, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 2, 2022
A Conceptual Framework for Life-Cycle Health Technology AssessmentErin Kirwin, Jeff Round, Ken Bond, et al.
Experimental & Translational Stroke Medicine|October 21, 2016
Therapeutic potential of the renin angiotensin system in ischaemic strokeMariana Moreira Coutinho Arroja, Emma Reid, Christopher McCabe
Pageof 15